共 52 条
[1]
Poirier P(2006)Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism Circulation 113 898-918
[2]
Giles TD(2008)Impact of obesity on cardiovascular disease Endocrinol Metab Clin North Am 37 663-84
[3]
Bray GA(2005)Safety of obesity drugs Expert Opin Drug Saf 4 1083-95
[4]
Zalesin KC(2009)What are the risks and the benefits of current and emerging weight-loss medications? Curr Diab Rep 9 368-1
[5]
Franklin BA(2010)Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation Circulation 121 1868-77
[6]
Miller WM(2007)Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2457-71
[7]
Greenway FL(2008)Sibutramine: current status as an anti-obesity drug and its future perspectives Expert Opin Pharmacother 9 2161-73
[8]
Caruso MK(2009)The use of sibutramine in the management of obesity and related disorders: an update Vasc Health Risk Manag 5 441-52
[9]
Robinson JR(2003)A benefit-risk assessment of sibutramine in the management of obesity Drug Saf 26 1027-48
[10]
Niswender KD(2008)Sibutramine: balancing weight loss benefit and possible cardiovascular risk Nutr Metab Cardiovasc Dis 18 337-41